US Edition
NorthStrive completes Phase 1 review for oral myostatin-engineered probiotic - BioTuesdays
Summary by biotuesdays.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
NorthStrive completes Phase 1 review for oral myostatin-engineered probiotic - BioTuesdays
NorthStrive Biosciences (NASDAQ:ELAB) announced the completion of a Phase I strategic research and literature synthesis for EL-22 (formerly BLS-M22), its first-in-class oral myostatin-engineered probiotic targeting muscle loss associated with GLP-1 weight loss drugs and age-related sarcopenia. According to NorthStrive, the analysis, conducted in collaboration with Yuva Biosciences and supported by AI-based scientific review technology from Yuva …
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
